Stoke Therapeutics, Inc. STOK Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Global Development Activity | $4.03M-32.5% | $5.97M-10.6% | $6.68M+109% | $3.2M+94.7% | $1.64M— | |
| IP License | $0— | $0— | $0— | $0-100% | $150.78M— | |
| Operating Expenses by Product | ||||||
| ADOA | -$1.86M-16.2% | -$1.6M+0.4% | -$1.61M+8.0% | -$1.75M-45.5% | -$1.2M+7.1% | |
| MECP2 | $0— | $0+100% | -$16K-108% | $200K+236% | -$147K+40.2% | |
| Other External Program Costs | -$3.18M-7.9% | -$2.95M-32.6% | -$2.22M-20.6% | -$1.84M-0.7% | -$1.83M+38.0% | |
| Other Non Program Costs Research And Development | -$1.68M-18.9% | -$1.41M+17.5% | -$1.71M-6.1% | -$1.62M-14.8% | -$1.41M-74.6% | |
| Other Non Program Costs Sales General And Administrative | -$5.16M— | —— | -$4.59M— | —— | -$4.79M— | |
| Payroll And Other Personnel Costs Research And Development | -$16.12M+2.0% | -$16.45M-30.3% | -$12.63M-8.7% | -$11.62M-5.5% | -$11.01M-5.4% | |
| Payroll And Other Personnel Costs Sales General And Administrative | -$11.06M— | —— | -$8.94M— | —— | -$8.93M— | |
| SYNGAP1 | -$745K+40.7% | -$1.26M-37.1% | -$917K-12.1% | -$818K-139% | -$342K+13.9% | |
| Zorevunersen | -$19.85M+8.4% | -$21.69M-2.8% | -$21.09M-85.3% | -$11.38M+35.6% | -$17.67M-116% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Stoke Therapeutics, Inc. break its business down?
- Stoke Therapeutics, Inc. (STOK) reports revenue by product across 4 parts — Global Development Activity, IP License, License and Service. Each is extracted from the segment footnotes and tracked over time.
- Where does Stoke Therapeutics, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Stoke Therapeutics, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.